

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mrs. NEELAM

AGE/ GENDER : 42 YRS/FEMALE **PATIENT ID** : 1749569

COLLECTED BY : 122503080010 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 08/Mar/2025 09:48 AM BARCODE NO. : 12507403 **COLLECTION DATE** : 08/Mar/2025 10:08AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 08/Mar/2025 01:42PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

| CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP | 168.34 | mg/dL | OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0 |
|--|--------|-------|---|
| TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC) | 147.61 | mg/dL | OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0 |
| HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION | 54.24 | mg/dL | LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0 |
| LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY | 84.58 | mg/dL | OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0 |
| NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY | 114.1 | mg/dL | OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0 |
| VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY | 29.52 | mg/dL | 0.00 - 45.00 |
| TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY | 484.29 | mg/dL | 350.00 - 700.00 |
| CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | 3.1 | RATIO | LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 |



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







A PIONEER DIAGNOSTIC CENTRE

NAME : Mrs. NEELAM

AGE/ GENDER : 42 YRS/FEMALE **PATIENT ID** : 1749569

COLLECTED BY REG. NO./LAB NO. : 122503080010

REFERRED BY **REGISTRATION DATE** : 08/Mar/2025 09:48 AM BARCODE NO. : 12507403 **COLLECTION DATE** : 08/Mar/2025 10:08AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 08/Mar/2025 01:42PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

| Test Name | Value | Unit | Biological Reference interval |
|---|-------------------|-------|---|
| 1 est Name | | | |
| LDL/HDL RATIO: SERUM | 1.56 | RATIO | MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 |
| by CALCULATED, SPECTROPHOTOMETRY | 1.50 | RATIO | MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0 |
| TRIGLYCERIDES/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY | 2.72 ^L | RATIO | 3.00 - 5.00 |

INTERPRETATION:

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

NAME : Mrs. NEELAM

AGE/ GENDER : 42 YRS/FEMALE **PATIENT ID** : 1749569

COLLECTED BY : 122503080010 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 08/Mar/2025 09:48 AM BARCODE NO. : 12507403 **COLLECTION DATE** : 08/Mar/2025 10:08AM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 08/Mar/2025 01:42PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

ENDOCRINOLOGY THYROID STIMULATING HORMONE (TSH)

THYROID STIMULATING HORMONE (TSH): SERUM

μIU/mL 0.35 - 5.50

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

3rd GENERATION, ULTRASENSITIVE

INTERPRETATION:

| AGE | REFFERENCE RANGE (μIU/mL) | | |
|---------------------|---------------------------|--|--|
| 0 – 5 DAYS | 0.70 - 15.20 | | |
| 6 Days – 2 Months | 0.70 – 11.00 | | |
| 3 – 11 Months | 0.70 - 8.40 | | |
| 1 – 5 Years | 0.70 – 7.00 | | |
| 6 – 10 Years | 0.60 - 5.50 | | |
| 11 - 15 | 0.50 - 5.50 | | |
| > 20 Years (Adults) | 0.27 - 5.50 | | |
| PRE | GNANCY | | |
| 1st Trimester | 0.10 - 3.00 | | |
| 2nd Trimester | 0.20 - 3.00 | | |
| 3rd Trimester | 0.30 - 4.10 | | |

NOTE:-TSH levels are subjected to circardian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50 %. Hence time of the day has influence on the measured serum TSH concentration.

USE: TSH controls biosynthesis and release of thyroid harmones T4 & T3. It is a sensitive measure of thyroid function, especially useful in early or subclinical hypothyroidism, before the patient develops any clinical findings or goitre or any other thyroid function abnormality.

INCREASED LEVELS:

- 1. Primary or untreated hypothyroidism, may vary from 3 times to more than 100 times normal depending on degree of hypofunction.
- 2. Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3. Hashimotos thyroiditis.
- 4.DRUGS: Amphetamines, Iodine containing agents and dopamine antagonist.
- 5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge.

DECREASED LEVELS:

- 1. Toxic multi-nodular goitre & Thyroiditis.
- 2. Over replacement of thyroid harmone in treatment of hypothyroidism.
- 3. Autonomously functioning Thyroid adenoma
- 4. Secondary pituatary or hypothalmic hypothyroidism
- 5. Acute psychiatric illness
- 6. Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

REPORTING DATE

: 08/Mar/2025 01:42PM

NAME : Mrs. NEELAM

AGE/ GENDER : 42 YRS/FEMALE **PATIENT ID** : 1749569

COLLECTED BY REG. NO./LAB NO. : 122503080010

REFERRED BY **REGISTRATION DATE** : 08/Mar/2025 09:48 AM BARCODE NO. : 12507403 **COLLECTION DATE** : 08/Mar/2025 10:08AM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name Value Unit **Biological Reference interval**

8. Pregnancy: 1st and 2nd Trimester LIMITATIONS:

CLIENT CODE.

1.TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

2. Autoimmune disorders may produce spurious results.

End Of Report



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)